{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:57:22Z","timestamp":1789516642825,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 25\u2010year\u2010old man presented with microangiopathic haemolytic anaemia and acute kidney injury. With a normal ADAMTS\u201013 level, negative faecal shiga\u2010toxin test and strong family history of atypical haemolytic uremic syndrome, he was commenced on eculizumab to good clinical response. Subsequent genetic testing revealed a heterozygous complement factor H mutation. Eculizumab was discontinued after 44\u2009months of treatment, and he relapsed within 6\u2009months, with the first sign being downtrending haptoglobin levels, with no other markers of haemolysis or thrombocytopaenia, 5\u2009weeks prior to development of acute kidney injury. He was recommenced on eculizumab and to date still remains on it. This case highlights the unusual pattern of relapse and discusses the considerations for eculizumab discontinuation in patients with stable atypical haemolytic uremic syndrome receiving maintenance therapy.<\/jats:p>","DOI":"10.1111\/nep.12931","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T04:56:29Z","timestamp":1486529789000},"page":"4-6","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab"],"prefix":"10.1111","volume":"22","author":[{"given":"Shi Zhou","family":"Choo","sequence":"first","affiliation":[{"name":"Department of Nephrology Monash Health  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Nephrology Monash Health  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715577613"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-60"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07916.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2011.11.013"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1763-z"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"e_1_2_6_9_1","first-page":"39","article-title":"Critical appraisal of eculizumab for atypical hemolytic uremic syndrome","volume":"7","author":"Palma LM","year":"2016","journal-title":"J Blood Med"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080811"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.434"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.04.010"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1622-z"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.039"},{"key":"e_1_2_6_16_1","author":"Pharmaceutical Benefits Scheme (PBS)","year":"2016","journal-title":"Eculizumab"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.12931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.12931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:13:42Z","timestamp":1695996822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.12931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":15,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/nep.12931"],"URL":"https:\/\/doi.org\/10.1111\/nep.12931","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"2017-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}